Global Opioid Tolerance Treatment Market Is Expected To Reach Around USD 2,290 Million By 2025

04-Jul-2019 | Zion Market Research

Zion Market Research has published a new report titled “Opioid Tolerance Treatment Market by Drug (Alpha2-Adrenoceptor Agonists, NMDA Antagonists, and Others), by Opioid Tolerance Type (Innate Tolerance and Acquired Tolerance), by Administration Route (Enteral and Parenteral), and by End-User (Hospitals & ASCs, Rehabilitation Centers, and Others): Global Market Perspective, Comprehensive Analysis, and Forecast, 2018–2025”. According to the report, the global opioid tolerance treatment market was USD 1,782 million in 2018 and is expected to generate USD 2,290 million by 2025, at a CAGR of 3.6% between 2019 and 2025.

Opioids are pain-relieving drugs that work with opioid receptors present in the human brain cell. The cell sends signals that change the perception of pain and uplifts the sense of pleasure in the body. Opioids are psychotropic substance derived from the opium poppy or developed in laboratories, such as heroin and morphine. The increasing number of orthopedic surgeries is one of the main growth drivers of the global opioid tolerance treatment market.

Request Sample Request Customization Buy Now

Browse the full “Opioid Tolerance Treatment Market by Drug (Alpha2-Adrenoceptor Agonists, NMDA Antagonists, and Others), by Opioid Tolerance Type (Innate Tolerance and Acquired Tolerance), by Administration Route (Enteral and Parenteral), and by End-User (Hospitals & ASCs, Rehabilitation Centers, and Others): Global Market Perspective, Comprehensive Analysis, and Forecast, 2018–2025” Report at https://www.zionmarketresearch.com/report/opioid-tolerance-treatment-market

Global Opioid Tolerance Treatment Market

The global opioid tolerance treatment market is fragmented on the basis of drug, administration route, opioid tolerance type, and end-user. Based on drug type, the market includes Alpha2-adrenoceptor agonists, NMDA antagonists, and others. Alpha2-adrenoceptor agonists are further segmented into Clonidine, Tizanidine, and others. The NMDA antagonists segment is further divided into Dextromethorphan, Ketamine, and others. Alpha2-adrenoceptor agonists accounted for the largest market share, i.e., more than 80%, and are expected to remain dominant over the forecast time period. This can be attributed to their improved efficacy for opioids tolerance and fewer side-effects.

By opioid tolerance type, the market is categorized into acquired and innate. Acquired tolerance dominated the global market in 2018, as it involves drug exposure that results in decreased side-effects.

By administration route, the market includes enteral and parenteral. In 2018, the parenteral segment accounted for the major share in the global opioids tolerance treatment market in 2018, due to the higher bioavailability of parenteral drugs and rapid action onset.

By end-user, the global market comprises hospitals and ASCs, rehabilitation centers, and others. Hospitals and ASCs dominated the opioid tolerance treatment market in 2018 globally, due to growing patient admissions for treating cancer and chronic pain along with these setting being equipped with better facilities.

The Asia Pacific region is expected to register a high growth rate in the global opioid tolerance treatment market, in terms of market share, over the estimated timeframe. North America accounted for the largest share of the global opioid tolerance treatment market in 2018, owing to the high prevalence of chronic diseases and pain associated with such diseases along with the increasing aging regional population, as geriatric people are more susceptible to pain and require a high dose of opioids for pain relief.

Some major players operating in the global opioid tolerance treatment market are Pfizer, GlaxoSmithKline, Boehringer Ingelheim, Teva Pharmaceutical, Mylan, Otsuka Pharmaceutical, Johnson & Johnson, Aurobindo Pharma, Acorda Therapeutics, and Zydus Cadila.

This report segments the global opioid tolerance treatment market into:

Global Opioid Tolerance Treatment Market: Drug Analysis

  • NMDA Antagonists
    • Ketamine
    • Dextromethorphan
    • Others
  • Alpha2-Adrenoceptor Agonists
    • Clonidine
    • Tizanidine
    • Others
  • Others

Global Opioid Tolerance Treatment Market: Opioid Tolerance Type Analysis

  • Innate Tolerance
  • Acquired Tolerance

Global Opioid Tolerance Treatment Market: Administration Route Analysis

  • Enteral
  • Parenteral

Global Opioid Tolerance Treatment Market: End-User Analysis

  • Hospitals and ASCs
  • Rehabilitation Centers
  • Others (Homecare Settings and Research Institutes)

Global Opioid Tolerance Treatment Market: Regional Analysis

  • North America
    • U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

About Us:
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com

Request Brochure
Latest Published Reports

View All Published Reports